BR112014018717A8 - Método para selecionar ou identificar um sujeito para terapia de antagonista de v1b - Google Patents

Método para selecionar ou identificar um sujeito para terapia de antagonista de v1b

Info

Publication number
BR112014018717A8
BR112014018717A8 BR112014018717A BR112014018717A BR112014018717A8 BR 112014018717 A8 BR112014018717 A8 BR 112014018717A8 BR 112014018717 A BR112014018717 A BR 112014018717A BR 112014018717 A BR112014018717 A BR 112014018717A BR 112014018717 A8 BR112014018717 A8 BR 112014018717A8
Authority
BR
Brazil
Prior art keywords
marker
identifying
selecting
subject
antagonist therapy
Prior art date
Application number
BR112014018717A
Other languages
English (en)
Other versions
BR112014018717A2 (pt
Inventor
a katz David
Van Gaalen Marcel
Original Assignee
Abbvie Inc
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Abbvie Deutschland filed Critical Abbvie Inc
Publication of BR112014018717A2 publication Critical patent/BR112014018717A2/pt
Publication of BR112014018717A8 publication Critical patent/BR112014018717A8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)

Abstract

MÉTODO PARA SELECIONAR OU IDENTIFICAR UM SUJEITO PARA TERAPIA DE ANTAGONISTA DE V1B. Fornecido aqui é um método para detectar um marcador de função de eixo HPA em uma amostra biológica. O método pode ser usado para determinar se um paciente é um candidato adequado para o tratamento com um antagonista de V1B. O marcador de HPA pode ser um marcador genômico, marcador não genômico, ou uma combinação destes. Dependendo do tipo de marcador de HPA, o método de detecção pode ser um imunoensaio ou genotipagem, por exemplo.
BR112014018717A 2012-03-13 2013-03-13 Método para selecionar ou identificar um sujeito para terapia de antagonista de v1b BR112014018717A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261610101P 2012-03-13 2012-03-13
PCT/EP2013/055147 WO2013135769A1 (en) 2012-03-13 2013-03-13 Method for selecting or identifying a subject for v1b antagonist therapy

Publications (2)

Publication Number Publication Date
BR112014018717A2 BR112014018717A2 (pt) 2017-06-20
BR112014018717A8 true BR112014018717A8 (pt) 2017-07-11

Family

ID=47846064

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014018717A BR112014018717A8 (pt) 2012-03-13 2013-03-13 Método para selecionar ou identificar um sujeito para terapia de antagonista de v1b

Country Status (14)

Country Link
US (1) US20130245038A1 (pt)
EP (1) EP2825891A1 (pt)
JP (1) JP2015512892A (pt)
KR (1) KR20140147837A (pt)
CN (1) CN104303060A (pt)
AU (1) AU2013231230A1 (pt)
BR (1) BR112014018717A8 (pt)
CA (1) CA2866220A1 (pt)
HK (1) HK1205789A1 (pt)
MX (1) MX2014011045A (pt)
RU (1) RU2014141059A (pt)
SG (1) SG11201405214YA (pt)
WO (1) WO2013135769A1 (pt)
ZA (1) ZA201406518B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140046407A1 (en) * 2001-08-31 2014-02-13 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
CN109030828A (zh) * 2018-06-21 2018-12-18 大连民族大学 一种检测组氨酸磷酸化蛋白的elisa检测试剂盒及检测方法
CN108845145A (zh) * 2018-06-21 2018-11-20 大连民族大学 一种检测组氨酸激酶活性的方法
CN114624344A (zh) * 2020-12-10 2022-06-14 中国科学院大连化学物理研究所 一种类固醇激素联合生物标志物及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1362776A (en) * 1970-07-17 1974-08-07 Wellcome Found Immunological reagent
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
ATE111083T1 (de) 1986-10-22 1994-09-15 Abbott Lab Chemilumineszierende acridinium- und phenantridiniumsalze.
US5241070A (en) 1988-09-26 1993-08-31 Ciba Corning Diagnostics Corp. Nucleophilic polysubstituted aryl acridinium esters and uses thereof
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
JPH05504841A (ja) 1990-09-14 1993-07-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途
JPH06506688A (ja) 1991-04-10 1994-07-28 バイオサイト・ダイアグノスティックス・インコーポレイテッド クロストークインヒビターおよびその使用
JP3290988B2 (ja) 1991-04-11 2002-06-10 バイオサイト・ダイアグノスティックス・インコーポレイテッド 多重リガンドを同時検出する新規接合体及び検定法
US5352803A (en) 1992-03-30 1994-10-04 Abbott Laboratories 5(6)-methyl substituted fluorescein derivatives
CA2131727A1 (en) 1992-03-30 1993-10-14 Diana E. Clarisse Reagents and methods for the detection and quantification of thyroxine in fluid samples
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
EP1386275A2 (en) 2000-07-18 2004-02-04 Correlogic Systems, Inc. A process for discriminating between biological states based on hidden patterns from biological data
US6890763B2 (en) 2001-04-30 2005-05-10 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons
US6989100B2 (en) 2002-05-09 2006-01-24 Ppd Biomarker Discovery Sciences, Llc Methods for time-alignment of liquid chromatography-mass spectrometry data
WO2003097237A2 (en) * 2002-05-13 2003-11-27 Becton, Dickinson, And Company Protease inhibitor sample collection system
WO2008137270A1 (en) * 2007-05-04 2008-11-13 H. Lundbeck A/S Methods of diagnosing and monitoring of npy y5 based disorders
EP2272044A4 (en) * 2008-03-12 2011-07-06 Ridge Diagnostics Inc INFLAMMATION BIOMARKERS FOR MONITORING DEPRESSION DISORDERS
WO2009130232A1 (en) * 2008-04-24 2009-10-29 Glaxo Group Limited Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors
CN102483405B (zh) * 2009-07-10 2015-12-02 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法

Also Published As

Publication number Publication date
JP2015512892A (ja) 2015-04-30
AU2013231230A8 (en) 2014-08-14
RU2014141059A (ru) 2016-04-27
ZA201406518B (en) 2018-05-30
SG11201405214YA (en) 2014-10-30
BR112014018717A2 (pt) 2017-06-20
CN104303060A (zh) 2015-01-21
EP2825891A1 (en) 2015-01-21
US20130245038A1 (en) 2013-09-19
HK1205789A1 (en) 2015-12-24
AU2013231230A1 (en) 2014-08-07
WO2013135769A1 (en) 2013-09-19
KR20140147837A (ko) 2014-12-30
CA2866220A1 (en) 2013-09-19
MX2014011045A (es) 2015-04-10

Similar Documents

Publication Publication Date Title
BR112015029318A2 (pt) marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
SV2017005577A (es) Metodos para diagnosticar y tratar el cancer
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
BR112015012297A2 (pt) conexões implícitas de gráfico social
BR112013003391A2 (pt) biomarcadores de câncer pancreático e usos dos mesmos
GB2519906A (en) Methods and systems for detecting biological components
BR112013020773A2 (pt) "método para a detecção localizada in situ de rna, método para a determinação da presença e da localização de uma sequência genética, conjunto de sondas em cadeado, uso do conjunto de sondas, kit e método para a identificação de uma célula"
BR112016004305A2 (pt) métodos diagnósticos e composições para tratamento de glioblastoma
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
BR112014009413A2 (pt) sistemas e métodos para proteger e administrar informação genômica e outras
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
BR112016001957A2 (pt) biossensor
AR065910A1 (es) Marcadores biologicos pronosticos de la respuesta de la artritis reumatoide a los antagonistas de los linfocitos b
BR112017009151A2 (pt) ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos
BR112014006432A2 (pt) biomarcadores do câncer de pulmão e seus usos
BR112017008218A2 (pt) métodos e composições para diagnóstico e prognóstico de lesão renal e insuficiência renal
BR112014018717A8 (pt) Método para selecionar ou identificar um sujeito para terapia de antagonista de v1b
MX2017003370A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
BRPI0620212B8 (pt) método de discriminação e de contagem de pelo menos duas populações de elementos biológicos portadoras de características específicas, e, utilização do método
MX2022014741A (es) Metodos para detectar bordetella.
BR112015029852A2 (pt) método para prever ou monitorar se um paciente que sofre de câncer ou uma doença autoimune responderá ou responde ao tratamento com um agonista de tlr-9, agonista de tlr-9 para uso em um método de tratamento de câncer, e kit para prever ou monitorar se um paciente que sofre de câncer ou doença autoimune irá responder ou responde ao tratamento com um agonista de tlr-9
BR112015004631A2 (pt) marcadores genéticos de resistência à mastite
BR112017017878A2 (pt) método, suporte e kit de coleta de ácido(s) nucleico(s)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]